drugset / Trial / NCT02248012
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Phase 2
Completed
38 enrolled
Haukeland University Hospital
Aarhus University Hospital · collabCopenhagen University Hospital, Denmark · collabRigshospitalet, Denmark · collabSahlgrenska University Hospital · collabSkane University Hospital · collabUllevaal University Hospital · collabUppsala University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To study the efficacy of everolimus combined with temozolomide as first-line treatment in advanced gastroenteropancreatic neuroendocrine carcinoma with a Ki67 of 20-55%, measured as disease control rate (non-progressive disease) at 6 months.
Timeline
- Start
- 2014-12
- Primary completion
- 2018-01
- Completion
- 2019-12-01
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | — |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | — |